Analysts have raised their price target for Adaptimmune Therapeutics from $0.98 to $1.50. This change reflects updated expectations for valuation and revised future earnings metrics.
What's in the News
- Adaptimmune Therapeutics has filed a Form 15 with the SEC to voluntarily deregister its American Depositary Shares under the Securities Exchange Act of 1934 (Key Developments).
- The company has been dropped from the Nasdaq Composite Index (Key Developments).
- Adaptimmune Therapeutics received a written notice from the Nasdaq Hearings Panel granting an exception period to regain compliance with the $1.00 minimum bid price rule until December 1, 2025 (Key Developments).
- A separate notice from Nasdaq Listing Qualifications Staff indicated that the company's Market Value of Listed Securities fell below the $35 million minimum required for continued listing. Adaptimmune has until March 10, 2026 to regain compliance (Key Developments).
- Adaptimmune was removed from the S&P Global BMI Index (Key Developments).
Valuation Changes
- Fair Value per share has increased from $0.98 to $1.50, marking a notable upward revision.
- Discount Rate has risen slightly from 13.28 percent to 13.46 percent.
- Revenue Growth expectations remain essentially unchanged at approximately 44.82 percent.
- Net Profit Margin has decreased marginally, moving from 16.40 percent to 15.79 percent.
- Future P/E ratio has climbed from 12.92x to 20.29x, which reflects a higher valuation multiple.
Have other thoughts on Adaptimmune Therapeutics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.